Intellia Therapeutics secures $400M non-dilutive debt facility with OrbiMed to fund commercial launch of CRISPR gene therapy ...

BW-20805 siRNA therapy shows 83-96% reduction in HAE attack rates in Phase II trial. Breakthrough results for hereditary ...

Acepodia's ACE723 dual-payload ADC wins FDA clearance for Phase I trial in hepatocellular carcinoma. First clinical entry for ...

Dimerix Limited secures AUD 34 million non-dilutive funding for Phase III FSGS trial. Discover how this funding advances ...

Innovent Biologics begins Phase I trial of IBI3042, a once-weekly oral GLP-1 agonist. Learn about this breakthrough in oral ...

Medicus Pharma licenses Pfizer's discontinued ADC candidate PF-08046031 for $27M upfront and over $1B in potential milestones ...

NeuShen Therapeutics closes $80M Series B funding to advance three CNS programs into global trials. Accelerating ...

Milestone Pharmaceuticals' etripamil nasal spray receives China NMPA clearance for PSVT treatment. First regulatory approval ...

Superluminal Medicines secures $60M Series B funding to advance MC4R agonist into Phase I trials for rare genetic obesity.

Soufflé Therapeutics launches Phase I/II trial of SFL-0821, an antibody-siRNA conjugate targeting DUX4 for ...

Four-year data confirms zorevunersen maintains seizure reductions and neurodevelopmental gains in Dravet syndrome. Stoke ...

FDA approves Zanvastro (zilganersen), the first disease-modifying treatment for Alexander disease in pediatric and adult ...